Evidence-Based Updates & Advocacy
On January 24, 2024, Azurity Pharmaceuticals, Inc., based in Woburn, Massachusetts, has initiated a voluntary recall of a specific lot (F230169A) of Zenzedi® CII (dextroamphetamine… Continue Reading Urgent Recall for Zenzedi® 30 mg Amidst Packaging Mix-Up
Published in BJPsych Open(Cambridge) on 22/01/2024 Suicide and the association of mental illness, particularly attention-deficit hyperactivity disorder (ADHD), with increased risk of suicide attempts and… Continue Reading ADHD Stimulant Treatment Cuts Suicide Risk!
Exposing the serious consequences of undiagnosed ADHD, this narrative calls urgently for early intervention. Unveil the shadows, protect vulnerable lives. Shadows of Undiagnosed ADHD In… Continue Reading Serious Consequences of Undiagnosed ADHD
